A study evaluating the effect of new formulation, food or a proton pump inhibitor on the relative bioavailability of the Glasdegib in healthy volunteers.

Trial Profile

A study evaluating the effect of new formulation, food or a proton pump inhibitor on the relative bioavailability of the Glasdegib in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Glasdegib (Primary) ; Rabeprazole (Primary) ; Glasdegib
  • Indications Acute myeloid leukaemia; Cancer; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jan 2018 New trial record
    • 01 Dec 2017 Primary endpoint (Bioavailability of Formulation A and Formulation B relative to the current diHCl-based reference formulation.) has been met as per the results published in the Cancer Chemotherapy and Pharmacology
    • 01 Dec 2017 Results published in the Cancer Chemotherapy and Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top